Try

CorMedix Inc. Common Stock

CRMDUnited States

5 filed reports · 340 financial concepts · 4 earnings calls · 0 media appearances

Filed reports

5 reports · Jun 2025 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR41,006Jun 2025 to Jun 2026
Annual · 10-KSEC EDGAR1656Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q210-QJun 30, 2026Aug 13, 2026347Open
FY2026 Q110-QMar 31, 2026May 14, 2026234Open
FY202510-KDec 31, 2025Mar 5, 2026656Open
FY2025 Q310-QSep 30, 2025Nov 12, 2025300Open
FY2025 Q210-QJun 30, 2025Aug 7, 2025125Open

Financial data

340 concepts · 1,662 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial334 concepts · 1,554 facts · Jun 2024 to Jun 2026

  • Restricted cash17 · Dec 2024 to Jun 2026
  • Adjustments to additional paid in capital share based compensation stock options requisite service period recognition11 · Jun 2024 to Jun 2026
  • Cash and cash equivalents at carrying value11 · Jun 2024 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents11 · Jun 2024 to Jun 2026
  • Comprehensive income net of tax11 · Jun 2024 to Jun 2026
  • General and administrative expense (US GAAP)11 · Jun 2024 to Jun 2026
  • Gross profit (US GAAP)11 · Jun 2024 to Jun 2026
  • Net income loss11 · Jun 2024 to Jun 2026
  • Nonoperating income expense11 · Jun 2024 to Jun 2026
  • Operating expenses (US GAAP)11 · Jun 2024 to Jun 2026
  • Operating income loss11 · Jun 2024 to Jun 2026
  • Other comprehensive income loss foreign currency transaction and translation adjustment net of tax11 · Jun 2024 to Jun 2026
  • Other comprehensive income loss tax11 · Jun 2024 to Jun 2026
  • Other comprehensive income unrealized holding gain loss on securities arising during period before tax11 · Jun 2024 to Jun 2026
  • Research and development expense11 · Jun 2024 to Jun 2026
  • Restricted stock value shares issued net of tax withholdings11 · Jun 2024 to Jun 2026
  • Revenue11 · Jun 2024 to Jun 2026
  • Selling and marketing expense (US GAAP)11 · Jun 2024 to Jun 2026
  • Share based compensation11 · Jun 2024 to Jun 2026
  • Stockholders equity (US GAAP)11 · Jun 2024 to Jun 2026
  • Stock issued during period value stock options exercised11 · Jun 2024 to Jun 2026
  • Amortization of intangibles10 · Sep 2024 to Jun 2026
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect10 · Sep 2024 to Jun 2026
  • Cost of revenue (US GAAP)10 · Jun 2024 to Mar 2026

Segment3 concepts · 66 facts · Jun 2024 to Jun 2026

  • General and administrative expense (US GAAP)23 · Jun 2024 to Jun 2026
  • Research and development expense23 · Jun 2024 to Jun 2026
  • Selling and marketing expense (US GAAP)20 · Jun 2024 to Jun 2026

Product2 concepts · 38 facts · Sep 2024 to Jun 2026

  • Revenue36 · Sep 2024 to Jun 2026
  • Amortization of intangible assets2 · Jun 2025 to Sep 2025

Geography1 concepts · 4 facts · Dec 2025

  • Income taxes paid net4 · Dec 2025

Segments

108 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement business segments5 members · 66 facts

  • Employee Expense18 · Jun 2024 to Dec 2025
  • Employee And Contracted Employee Expense15 · Jun 2024 to Jun 2026
  • Other General And Administrative11 · Jun 2024 to Jun 2026
  • Other Research And Development11 · Jun 2024 to Jun 2026
  • Other Selling And Marketing11 · Jun 2024 to Jun 2026

Product or service6 members · 38 facts

  • Defen Cath10 · Sep 2024 to Jun 2026
  • Product10 · Sep 2024 to Jun 2026
  • Contract Revenue7 · Mar 2025 to Jun 2026
  • Melinta Portfolio7 · Mar 2025 to Jun 2026
  • Grant Income2 · Jun 2025 to Jun 2026
  • License2 · Jun 2025 to Sep 2025

Statement geographical4 members · 4 facts

  • MA1 · Dec 2025
  • SC1 · Dec 2025
  • TN1 · Dec 2025
  • TX1 · Dec 2025

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

4 calls · Nov 2025 to Aug 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q2Aug 13, 2026
  • FY2026 Q1May 14, 2026
  • FY2025 Q4Mar 5, 2026
  • FY2025 Q3Nov 12, 2025

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.

CorMedix Inc. Common Stock (CRMD) data · FactIQ